Dr. Amy Porter is a pharmacologist by training with over 10 years of experience in the pharmaceutical industry leading programs in Neuroscience drug discovery in Psychiatry, Neurodegeneration, and Pain at Eli Lilly and Company and Amgen.
Amy received her Bachelor of Science degree in Biochemistry and her Doctorate degree in Pharmacology and Toxicology from the University of Arizona. As a post-doctoral fellow at Eli Lilly and Company, Amy led a team of researchers from multiple disciplines that discovered a novel endogenous cannabinoid, Virodhamine.
Prior to joining C-Path, Amy ran an in vitro pharmacology laboratory at Eli Lilly and Company with a focus on the role of the endogenous cannabinoid system and cholinergic receptors in brain diseases. At Amgen San Francisco, Amy’s laboratory in the Neuroscience division led efforts from target validation to clinical development and cross functional drug development teams in pain and psychiatry.
Amy’s experience also includes scientific and regulatory writing as a consultant for non-profits and government agencies. Amy also worked as an independent in vitro pharmacology consultant for a pharmaceutical company.
Currently, Amy is the Executive Director of the Huntington’s Disease Regulatory Science Consortium (HD-RSC), which aims to bring together the Huntington’s disease community to share data in order to provide tools to support Huntington’s disease drug development.